IgD Myeloma: Clinical Features and Outcome from a Multicenter Retrospective Study in Chinese and Korean of 308 Patients from Asian Myeloma Network (AMN) Project

Juan Du,Weijun Fu,Jae Hoon Lee,Chunyang Zhang,Kihyun Kim,Ai Jun Liu,Jin Lu,Cheolwon Suh,Min Kyoung Kim,Wenming Chen,Jin Liu,Hua Jiang,Jian Hou
DOI: https://doi.org/10.1182/blood.v130.suppl_1.5409.5409
IF: 20.3
2017-01-01
Blood
Abstract:IgD myeloma is a rare hematologic malignancy for which clinical and biological features and patient outcomes have not been extensively studied. However, previous studies found 3.1% IgD myeloma prevalence in Asian myeloma patients, and with the high incidence of 6%, especially for younger than 50 years with 10.3% in Chinese myeloma patients (Kim K. et al. Am J Hematol. 2014, Lu J. et al. Drug Des Devel Ther. 2016). Therefore, to further assess the frequency and the specific characteristics and evaluate the outcome of patients with IgD myeloma, we carried out a multicenter retrospective study in Chinese and Korean patients from AMN project with diagnosis of IgD myeloma.
What problem does this paper attempt to address?